YI Quote, Financials, Valuation and Earnings

China Pharma Holding has a net margin of -0.48% compared to 111's net margin of -101.61%. 111's return on equity of -89.07% beat China Pharma Holding's return on equity of -66.27%.

111 has a consensus price target of --, signalling upside risk potential of 582.29%. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that 111 has higher upside potential than China Pharma Holding, analysts believe 111 is more attractive than China Pharma Holding.

111 has a beta of 0.414, which suggesting that the stock is 58.65% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.874%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

111 quarterly revenues are $502.9M, which are larger than China Pharma Holding quarterly revenues of $1.1M. 111's net income of -$2.4M is lower than China Pharma Holding's net income of -$1.1M. Notably, 111's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.04x versus 0.45x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

Dr Reddy's Laboratories has a net margin of -0.48% compared to 111's net margin of 15.66%. 111's return on equity of -89.07% beat Dr Reddy's Laboratories's return on equity of 19.35%.

111 has a consensus price target of --, signalling upside risk potential of 582.29%. On the other hand Dr Reddy's Laboratories has an analysts' consensus of $14.11 which suggests that it could grow by 0.85%. Given that 111 has higher upside potential than Dr Reddy's Laboratories, analysts believe 111 is more attractive than Dr Reddy's Laboratories.

111 has a beta of 0.414, which suggesting that the stock is 58.65% less volatile than S&P 500. In comparison Dr Reddy's Laboratories has a beta of 0.533, suggesting its less volatile than the S&P 500 by 46.687%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dr Reddy's Laboratories offers a yield of 0.62% to investors and pays a quarterly dividend of $0.10 per share. 111 pays -- of its earnings as a dividend. Dr Reddy's Laboratories pays out 11.94% of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

111 quarterly revenues are $502.9M, which are smaller than Dr Reddy's Laboratories quarterly revenues of $956.9M. 111's net income of -$2.4M is lower than Dr Reddy's Laboratories's net income of $149.8M. Notably, 111's price-to-earnings ratio is -- while Dr Reddy's Laboratories's PE ratio is 32.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.04x versus 3.65x for Dr Reddy's Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -0.48% compared to 111's net margin of --. 111's return on equity of -89.07% beat Sinovac Biotech's return on equity of -1.05%.

111 has a consensus price target of --, signalling upside risk potential of 582.29%. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that 111 has higher upside potential than Sinovac Biotech, analysts believe 111 is more attractive than Sinovac Biotech.

111 has a beta of 0.414, which suggesting that the stock is 58.65% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

111 quarterly revenues are $502.9M, which are larger than Sinovac Biotech quarterly revenues of --. 111's net income of -$2.4M is higher than Sinovac Biotech's net income of --. Notably, 111's price-to-earnings ratio is -- while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.04x versus 1.50x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -0.48% compared to 111's net margin of -40.75%. 111's return on equity of -89.07% beat Zai Lab's return on equity of -35.53%.

111 has a consensus price target of --, signalling upside risk potential of 582.29%. On the other hand Zai Lab has an analysts' consensus of $52.39 which suggests that it could grow by 95.93%. Given that 111 has higher upside potential than Zai Lab, analysts believe 111 is more attractive than Zai Lab.

111 has a beta of 0.414, which suggesting that the stock is 58.65% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.054%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

111 quarterly revenues are $502.9M, which are larger than Zai Lab quarterly revenues of $102.3M. 111's net income of -$2.4M is higher than Zai Lab's net income of -$41.7M. Notably, 111's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.04x versus 7.33x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.